Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Diabetes

Free Subscription Articles published in Ann Intern Med Retrieve available abstracts of 75 articles: HTML format

Single Articles

September 2025
1. WEITZ HH, Merli GJ
   Annals Consult Guys - Diabetes Issues in Ambulatory Surgery.
   Ann Intern Med. 2025;178:e2504052CG.
   PubMed    
   
   
   
2. ADES M, Anand SS
   In symptomatic peripheral artery disease with T2D, semaglutide increased maximum walking distance at 1 y.
   Ann Intern Med. 2025;178:JC100.
   PubMed     Abstract available
   
   
   August 2025
3. RUIZ-CANELA M, Corella D, Martinez-Gonzalez MA, Babio N, et al
   Comparison of an Energy-Reduced Mediterranean Diet and Physical Activity Versus an Ad Libitum Mediterranean Diet in the Prevention of Type 2 Diabetes : A Secondary Analysis of a Randomized Controlled Trial.
   Ann Intern Med. 2025 Aug 26. doi: 10.7326/ANNALS-25-00388.
   PubMed     Abstract available
   
   
   
4. 
   Summary for Patients: Comparison of an Energy-Reduced Mediterranean Diet and Physical Activity Versus an Ad Libitum Mediterranean Diet in the Prevention of Type 2 Diabetes.
   Ann Intern Med. 2025 Aug 26. doi: 10.7326/ANNALS-25-00388.
   PubMed    
   
   
   
5. HERRING SJ, Tripicchio GL
   Reducing Diabetes Risk Through the Mediterranean Diet.
   Ann Intern Med. 2025 Aug 26. doi: 10.7326/ANNALS-25-02748.
   PubMed    
   
   
   
6. NADGIR U, Ali SR, Gogate J, Shaw W, et al
   Treatment With Canagliflozin Versus Placebo in Children and Adolescents With Type 2 Diabetes : A Randomized Clinical Trial.
   Ann Intern Med. 2025 Aug 5. doi: 10.7326/ANNALS-24-04017.
   PubMed     Abstract available
   
   
   
7. 
   Summary for Patients: Treatment With Canagliflozin Versus Placebo in Children and Adolescents With Type 2 Diabetes.
   Ann Intern Med. 2025 Aug 5. doi: 10.7326/ANNALS-24-04017.
   PubMed    
   
   
   
8. CENTOR RM, Billings LK
   Annals On Call - Comparison of Dose Escalation Versus Switching to Tirzepatide When Diabetes Control Is Inadequate With Dulaglutide.
   Ann Intern Med. 2025 Aug 5:e2503404OC. doi: 10.7326/ANNALS-25-03404.
   PubMed    
   
   
   
9. BRADY RP, Shah AS
   Expanding the Treatment Vault: Canagliflozin in Youth With Type 2 Diabetes.
   Ann Intern Med. 2025 Aug 5. doi: 10.7326/ANNALS-25-02805.
   PubMed    
   
   
   
10. CENTOR RM, Kip K, Saeed A
    Web Exclusive. Annals On Call - Semaglutide Versus Dulaglutide or Empagliflozin: Death and Cardiovascular Outcomes for Patients With Type 2 Diabetes.
    Ann Intern Med. 2025;178:e2503594OC.
    PubMed    
    
    
    
11. LAU D, Senior P
    In insulin-treated T2D, automated insulin delivery reduced HbA(1c) without increasing hypoglycemic events vs. usual care at 13 wk.
    Ann Intern Med. 2025;178:JC95.
    PubMed     Abstract available
    
    
    July 2025
12. PLASCENCIA-VILLA G, Xu R, Perry G
    Potential Effects of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Diabetes and High Risk for Dementia.
    Ann Intern Med. 2025 Jul 22. doi: 10.7326/ANNALS-25-02362.
    PubMed    
    
    
    
13. WU Z, Sheng C, Guo Z, Zheng Y, et al
    Association of Weekend Warrior and Other Physical Activity Patterns With Mortality Among Adults With Diabetes : A Cohort Study.
    Ann Intern Med. 2025 Jul 22. doi: 10.7326/ANNALS-25-00640.
    PubMed     Abstract available
    
    
    
14. SIGAL RJ, Boule NG
    Physical Activity in Type 2 Diabetes: Could One or Two Weekly Sessions Be Enough?
    Ann Intern Med. 2025 Jul 22. doi: 10.7326/ANNALS-25-02522.
    PubMed    
    
    
    
15. INOUE K, Saliba D, Gotanda H, Moin T, et al
    Glucagon-Like Peptide-1 Receptor Agonists and Incidence of Dementia Among Older Adults With Type 2 Diabetes : A Target Trial Emulation.
    Ann Intern Med. 2025 Jul 22. doi: 10.7326/ANNALS-24-02648.
    PubMed     Abstract available
    
    
    
16. NOH Y, Yin H, Yu OHY, Bitton A, et al
    Glucagon-Like Peptide-1 Receptor Agonists and Risk for Gastroesophageal Reflux Disease in Patients With Type 2 Diabetes : A Population-Based Cohort Study.
    Ann Intern Med. 2025 Jul 15. doi: 10.7326/ANNALS-24-03420.
    PubMed     Abstract available
    
    
    
17. BANDI SSS, Montori VM
    In high-risk type 2 diabetes, adding oral semaglutide to standard care reduced MACE at a mean 48 mo.
    Ann Intern Med. 2025 Jul 1. doi: 10.7326/ANNALS-25-02173.
    PubMed     Abstract available
    
    
    
18. SHAHID M, Gandhi GY
    In patients with diabetes and previous MI, high-dose multivitamins and minerals did not reduce CV events.
    Ann Intern Med. 2025 Jul 1. doi: 10.7326/ANNALS-25-02174.
    PubMed     Abstract available
    
    
    June 2025
19. SAEED A, Mulukutla SR, Thoma F, Lemon L, et al
    Comparison of Semaglutide or Dulaglutide Versus Empagliflozin for Risk for Death and Cardiovascular Outcomes Among Patients With Type 2 Diabetes : Two Target Trial Emulation Studies.
    Ann Intern Med. 2025 Jun 17. doi: 10.7326/ANNALS-24-00775.
    PubMed     Abstract available
    
    
    
20. 
    Summary for Patients: Semaglutide or Dulaglutide Versus Empagliflozin for Risk for Death and Cardiovascular Outcomes Among Patients With Type 2 Diabetes.
    Ann Intern Med. 2025 Jun 17. doi: 10.7326/ANNALS-24-00775.
    PubMed    
    
    
    
21. CENTOR RM, Moiz A
    Annals On Call - Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss in the Absence of Diabetes.
    Ann Intern Med. 2025 Jun 3:e2502205OC. doi: 10.7326/ANNALS-25-02205.
    PubMed    
    
    
    
22. THAKKAR A, Newby LK
    In type 2 diabetes with CKD and additional CV risk factors, sotagliflozin reduced total MACE vs. placebo at a median 14 mo.
    Ann Intern Med. 2025 Jun 3. doi: 10.7326/ANNALS-25-01791.
    PubMed     Abstract available
    
    
    May 2025
23. QASEEM A, Basch P, Campos K, MacDonald ST, et al
    Quality Indicators for Diabetes in Adults: A Review of Performance Measures by the American College of Physicians.
    Ann Intern Med. 2025 May 6. doi: 10.7326/ANNALS-24-03770.
    PubMed     Abstract available
    
    
    
24. LAU D
    In adults with overweight or obesity and without diabetes, GLP-1 RAs increase weight loss vs. placebo.
    Ann Intern Med. 2025 May 6. doi: 10.7326/ANNALS-25-01325.
    PubMed     Abstract available
    
    
    
25. OSTROMINSKI JW, Ortega-Montiel J, Tesfaye H, Alix C, et al
    Trends in Utilization of Glucose- and Weight-Lowering Medications After Tirzepatide Approval in the United States : A Population-Based Cohort Study.
    Ann Intern Med. 2025;178:620-633.
    PubMed     Abstract available
    
    
    April 2025
26. MAKAM AN, Bailey L, Anderson N, Bellitti K, et al
    Availability of Cardioprotective Medications for Type 2 Diabetes in the Medicaid Program.
    Ann Intern Med. 2025 Apr 22. doi: 10.7326/ANNALS-24-01449.
    PubMed     Abstract available
    
    
    
27. BILLINGS LK, Winne L, Sharma P, Gomez-Valderas E, et al
    Comparison of Dose Escalation Versus Switching to Tirzepatide Among People With Type 2 Diabetes Inadequately Controlled on Lower Doses of Dulaglutide : A Randomized Clinical Trial.
    Ann Intern Med. 2025 Apr 4. doi: 10.7326/ANNALS-24-03849.
    PubMed     Abstract available
    
    
    
28. 
    Summary for Patients: Comparison of Dose Escalation Versus Switching to Tirzepatide Among People With Type 2 Diabetes Inadequately Controlled on Lower Doses of Dulaglutide.
    Ann Intern Med. 2025 Apr 4. doi: 10.7326/ANNALS-24-03849.
    PubMed    
    
    
    
29. SHADBOLT C, Elkin J, Schilling C, Hua X, et al
    National Trends in Glucagon-Like Peptide-1 Receptor Agonist Use in Adults Without Diabetes, 2018 to 2022.
    Ann Intern Med. 2025 Apr 1. doi: 10.7326/ANNALS-24-02878.
    PubMed    
    
    
    
30. CENTOR RM, Maciejewski ML, Sloan C
    Annals On Call - Health Expenditures of Patients With Diabetes After Bariatric Surgery.
    Ann Intern Med. 2025;178:e2501511OC.
    PubMed    
    
    
    
31. AMAN M, Jeevananthan A, Martinez-Cruz M, Namasingh N, et al
    Endocrinology: What You May Have Missed in 2024.
    Ann Intern Med. 2025 Apr 1. doi: 10.7326/ANNALS-25-00990.
    PubMed     Abstract available
    
    
    March 2025
32. OSERAN AS, Aggarwal R, Figueroa J, Joynt Maddox KE, et al
    Prevalence of Chronic Medical Conditions Among Medicare Advantage and Traditional Medicare Beneficiaries.
    Ann Intern Med. 2025;178:327-335.
    PubMed     Abstract available
    
    
    February 2025
33. TANG H, Lu Y, Donahoo WT, Westen SC, et al
    Glucagon-Like Peptide-1 Receptor Agonists and Risk for Depression in Older Adults With Type 2 Diabetes : A Target Trial Emulation Study.
    Ann Intern Med. 2025 Feb 25. doi: 10.7326/ANNALS-24-01347.
    PubMed     Abstract available
    
    
    January 2025
34. MACIEJEWSKI ML, Zepel L, Smith VA, Arterburn DE, et al
    Health Expenditures of Patients With Diabetes After Bariatric Surgery: Comparing Gastric Bypass and Sleeve Gastrectomy.
    Ann Intern Med. 2025 Jan 28. doi: 10.7326/ANNALS-24-00480.
    PubMed     Abstract available
    
    
    
35. 
    Annals Video Summary - Efficacy and Safety of GLP-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes.
    Ann Intern Med. 2025 Jan 7:e2403525VS. doi: 10.7326/ANNALS-24-03525.
    PubMed    
    
    
    
36. 
    Summary for Patients: Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes.
    Ann Intern Med. 2025 Jan 7. doi: 10.7326/ANNALS-24-01590.
    PubMed    
    
    
    
37. MOIZ A, Filion KB, Toutounchi H, Tsoukas MA, et al
    Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials.
    Ann Intern Med. 2025 Jan 7. doi: 10.7326/ANNALS-24-01590.
    PubMed     Abstract available
    
    
    
38. LARIOS F, Gionfriddo MR, Montori VM
    In T1D, weekly efsitora was noninferior to daily degludec for reducing HbA(1c) but increased severe hypoglycemia at 26 wk.
    Ann Intern Med. 2025;178:JC11.
    PubMed     Abstract available
    
    
    
39. LARIOS F, Gionfriddo MR, Montori VM
    In insulin-naive T2D, weekly efsitora was noninferior to daily degludec for reducing HbA(1c) at 52 wk.
    Ann Intern Med. 2025;178:JC10.
    PubMed     Abstract available
    
    
    December 2024
40. VASSILOPOULOS S, Mylonakis E
    After COVID-19 diagnosis, risk for incident type 2 diabetes was elevated for up to 2 y.
    Ann Intern Med. 2024 Dec 3. doi: 10.7326/ANNALS-24-02887.
    PubMed     Abstract available
    
    
    
41. GIANCHANDANI R, Wei M, Demidowich A
    Management of Hyperglycemia in Hospitalized Patients.
    Ann Intern Med. 2024;177:ITC177-ITC192.
    PubMed     Abstract available
    
    
    November 2024
42. ZHU D, Herrington WG
    In adults with BMI >/=27 kg/m(2) and CVD, but without diabetes, semaglutide reduced MACE, regardless of baseline HbA(1c) level.
    Ann Intern Med. 2024 Nov 5. doi: 10.7326/ANNALS-24-02457.
    PubMed     Abstract available
    
    
    
43. MAHER M, Dinneen S
    In T2D, SGLT-2 inhibitor effects on CV and kidney outcomes were consistent regardless of GLP-1 receptor agonist use.
    Ann Intern Med. 2024;177:JC124.
    PubMed     Abstract available
    
    
    
44. ZHU D, Herrington WG
    In HF, T2D, CKD, or atherosclerotic CVD, SGLT2 inhibitors reduce HF hospitalizations and CV mortality.
    Ann Intern Med. 2024;177:JC123.
    PubMed     Abstract available
    
    
    October 2024
45. FITCH KV, Zanni MV, Manne-Goehler J, Diggs MR, et al
    Diabetes Risk Factors in People With HIV Receiving Pitavastatin Versus Placebo for Cardiovascular Disease Prevention : A Randomized Trial.
    Ann Intern Med. 2024 Oct 8. doi: 10.7326/ANNALS-24-00944.
    PubMed     Abstract available
    
    
    
46. HONG B, Bea S, Ko HY, Kim WJ, et al
    Sodium-Glucose Cotransporter-2 Inhibitors, Dulaglutide, and Risk for Dementia : A Population-Based Cohort Study.
    Ann Intern Med. 2024;177:1319-1329.
    PubMed     Abstract available
    
    
    September 2024
47. COLLISTER D, Pannu N
    In T2DM with CKD, semaglutide reduced major kidney disease events at 3 y.
    Ann Intern Med. 2024;177:JC98.
    PubMed     Abstract available
    
    
    
48. YEO YH, Rezaie A, Hsieh TY, Hu X, et al
    Shifting Trends in the Indication of Glucagon-like Peptide-1 Receptor Agonist Prescriptions: A Nationwide Analysis.
    Ann Intern Med. 2024;177:1289-1291.
    PubMed    
    
    
    August 2024
49. CHAITOFF A, Bendicksen L, Feldman WB, Zheutlin AR, et al
    Estimating New Eligibility and Maximum Costs of Expanded Medicare Coverage of Semaglutide for Cardiovascular Risk Prevention.
    Ann Intern Med. 2024 Aug 27. doi: 10.7326/ANNALS-24-00308.
    PubMed    
    
    
    
50. KANJEE Z, Brown FM, Taxin ZH, Smetana GW, et al
    How Would You Treat This Inpatient With Type 2 Diabetes Mellitus? Grand Rounds Discussion From Beth Israel Deaconess Medical Center.
    Ann Intern Med. 2024 Aug 13. doi: 10.7326/ANNALS-24-01100.
    PubMed     Abstract available
    
    
    July 2024
51. WANG W, Volkow ND, Berger NA, Davis PB, et al
    Association of Semaglutide With Tobacco Use Disorder in Patients With Type 2 Diabetes : Target Trial Emulation Using Real-World Data.
    Ann Intern Med. 2024 Jul 30. doi: 10.7326/M23-2718.
    PubMed     Abstract available
    
    
    
52. TANG H, Lu Y, Donahoo WT, Shao H, et al
    Glucagon-Like Peptide-1 Receptor Agonists and Risk for Suicidal Ideation and Behaviors in U.S. Older Adults With Type 2 Diabetes : A Target Trial Emulation Study.
    Ann Intern Med. 2024 Jul 16. doi: 10.7326/M24-0329.
    PubMed     Abstract available
    
    
    
53. 
    Summary for Patients: Glucagon-Like Peptide-1 Receptor Agonists and Risk for Suicidal Ideation and Behaviors in U.S. Older Adults With Type 2 Diabetes.
    Ann Intern Med. 2024 Jul 16. doi: 10.7326/P24-0004.
    PubMed    
    
    
    
54. CENTOR RM, Crandall CJ
    Annals On Call - ACP Recommendation: Pharmacologic Treatment of Type 2 Diabetes.
    Ann Intern Med. 2024;177:e2401521OC.
    PubMed    
    
    
    
55. TANNER M
    In T1DM without CVD, the LIFE-T1D model predicted lifetime risk for CVD and non-CVD mortality.
    Ann Intern Med. 2024;177:JC83.
    PubMed     Abstract available
    
    
    
56. CHIU YH, Huybrechts KF, Patorno E, Yland JJ, et al
    Metformin Use in the First Trimester of Pregnancy and Risk for Nonlive Birth and Congenital Malformations: Emulating a Target Trial Using Real-World Data.
    Ann Intern Med. 2024;177:862-870.
    PubMed     Abstract available
    
    
    June 2024
57. CRAWFORD AL, Laiteerapong N
    Type 2 Diabetes.
    Ann Intern Med. 2024 Jun 11. doi: 10.7326/AITC202406180.
    PubMed     Abstract available
    
    
    
58. SMETANA GW, Romeo GR, Rosas SE, Burns RB, et al
    How Would You Manage This Patient With Type 2 Diabetes and Chronic Kidney Disease? Grand Rounds Discussion From Beth Israel Deaconess Medical Center.
    Ann Intern Med. 2024 Jun 11. doi: 10.7326/M24-0764.
    PubMed     Abstract available
    
    
    May 2024
59. LAINE C, Moyer DV, Qaseem A
    Newer Pharmacologic Treatments for Type 2 Diabetes.
    Ann Intern Med. 2024 May 28. doi: 10.7326/ANNALS-24-00698.
    PubMed    
    
    
    
60. O'BRIEN C, Dinneen SF
    In type 2 diabetes, the effectiveness and side effects of GLP-1 RAs vary.
    Ann Intern Med. 2024 May 7. doi: 10.7326/J24-0028.
    PubMed     Abstract available
    
    
    
61. BATES ER
    In patients with type 2 diabetes and recent MI, colchicine reduced a composite CV outcome at 23 mo.
    Ann Intern Med. 2024 May 7. doi: 10.7326/J24-0026.
    PubMed     Abstract available
    
    
    
62. MARUTHUR NM, Pilla SJ, White K, Wu B, et al
    Effect of Isocaloric, Time-Restricted Eating on Body Weight in Adults With Obesity : A Randomized Controlled Trial.
    Ann Intern Med. 2024;177:549-558.
    PubMed     Abstract available
    
    
    April 2024
63. YEN FS, Hwu CM, Liu JS, Wu YL, et al
    Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Dialysis and Cardiovascular Disease in Patients With Stage 5 Chronic Kidney Disease.
    Ann Intern Med. 2024 Apr 30. doi: 10.7326/M23-1874.
    PubMed     Abstract available
    
    
    
64. DRAKE T, Landsteiner A, Langsetmo L, MacDonald R, et al
    Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Systematic Review and Network Meta-analysis for the American College of Physicians.
    Ann Intern Med. 2024 Apr 19. doi: 10.7326/M23-1490.
    PubMed     Abstract available
    
    
    
65. SCHOUSBOE JT, Landsteiner A, Drake T, Sultan S, et al
    Cost-Effectiveness of Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Systematic Review of Cost-Effectiveness Studies for the American College of Physicians.
    Ann Intern Med. 2024 Apr 19. doi: 10.7326/M23-1492.
    PubMed     Abstract available
    
    
    
66. QASEEM A, Obley AJ, Shamliyan T, Hicks LA, et al
    Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Clinical Guideline From the American College of Physicians.
    Ann Intern Med. 2024 Apr 19. doi: 10.7326/M23-2788.
    PubMed     Abstract available
    
    
    
67. SYED FZ
    Pharmacologic Treatments in Adults With Type 2 Diabetes: Cost-Effectiveness and Comorbidity Considerations.
    Ann Intern Med. 2024 Apr 19. doi: 10.7326/M24-0861.
    PubMed    
    
    
    
68. 
    Annals Video Summary - Newer Pharmacologic Treatments in Adults With Type 2 Diabetes.
    Ann Intern Med. 2024 Apr 19:eM231554. doi: 10.7326/M23-1554.
    PubMed    
    
    
    
69. 
    Visual Guideline - Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Visual Clinical Guideline From the American College of Physicians.
    Ann Intern Med. 2024 Apr 19:eM240803. doi: 10.7326/M24-0803.
    PubMed     Abstract available
    
    
    
70. KELSEY M, Newby LK
    In higher-risk, statin-intolerant adults with diabetes, bempedoic acid reduced MACE at a median 3 y.
    Ann Intern Med. 2024 Apr 2. doi: 10.7326/J24-0016.
    PubMed     Abstract available
    
    
    
71. HWANG JH, Hsu CY
    In CKD, empagliflozin reduced kidney disease progression at a median 2 y, regardless of primary kidney disease type.
    Ann Intern Med. 2024;177:JC40.
    PubMed     Abstract available
    
    
    
72. EGAN AM
    In T2DM, periconceptional, noninsulin, second-line antidiabetes medications were not linked to major congenital malformations vs. insulin.
    Ann Intern Med. 2024;177:JC47.
    PubMed     Abstract available
    
    
    March 2024
73. GARABEDIAN LF, Zhang F, Costa R, Argetsinger S, et al
    Association of State Insulin Out-of-Pocket Caps With Insulin Cost-Sharing and Use Among Commercially Insured Patients With Diabetes : A Pre-Post Study With a Control Group.
    Ann Intern Med. 2024 Mar 26. doi: 10.7326/M23-1965.
    PubMed     Abstract available
    
    
    
74. KOUTROUMPAKIS E, Deswal A
    In adults with overweight or obesity and CVD, but without diabetes, semaglutide reduced MACE at a mean 40 mo.
    Ann Intern Med. 2024 Mar 5. doi: 10.7326/J24-0008.
    PubMed     Abstract available
    
    
    
75. PERSELL SD, Petito LC, Lee JY, Meeker D, et al
    Reducing Care Overuse in Older Patients Using Professional Norms and Accountability : A Cluster Randomized Controlled Trial.
    Ann Intern Med. 2024;177:324-334.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Diabetes is free of charge.